Hospital
Drew Memorial Hospital, INC.
Drew Memorial Hospital, INC. was paid $3.78M by Medicaid between Jan 2018 and Dec 2023, across 175 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 11% of everything it billed.
33Billing provider infoDREW MEMORIAL HOSPITAL, INC.
MONTICELLO, AR 71655
MONTICELLO, AR 71655
33aNPI1023363348assigned 07/24/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.78M
24GClaims311,297
24DCodes billed175
24AFirst – last monthJan 2018 – Dec 2023
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#20 of 49
Median peer was paid$2.62M
This provider vs. median1.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40,933 | $487K | |
| 2019 | 60,395 | $653K | |
| 2020 | 56,310 | $616K | |
| 2021 | 52,339 | $680K | |
| 2022 | 55,913 | $712K | |
| 2023 | 45,407 | $633K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 11% | 11,481 | 2,656 | $411K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 6.7% | 4,699 | 3,689 | $252K |
| 80053 | Comprehensive metabolic panel | 6.1% | 25,697 | 18,199 | $230K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.9% | 4,746 | 1,005 | $185K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 2,147 | 1,668 | $156K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.2% | 4,369 | 2,735 | $119K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.0% | 5,238 | 3,683 | $115K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.9% | 5,735 | 2,108 | $111K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.7% | 2,683 | 2,356 | $104K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.7% | 2,682 | 2,355 | $103K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.5% | 2,606 | 2,288 | $95K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 1,906 | 754 | $86K |
163 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 14,825 | $84K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 819 | $82K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.0% | 5,180 | $76K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.9% | 2,078 | $72K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.6% | 1,464 | $62K |
| 83880 | 1.5% | 3,759 | $57K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 1.3% | 6,928 | $51K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.3% | 261 | $49K |
| 74178 | 1.3% | 416 | $49K | |
| 99283 | Emergency room visit (moderate) | 1.2% | 1,743 | $47K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.2% | 397 | $44K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 6,994 | $43K |
| 85027 | 1.1% | 9,536 | $42K | |
| 99284 | Emergency room visit (serious) | 1.1% | 2,962 | $42K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.1% | 3,473 | $42K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 747 | $38K |
| 87088 | <1% | 5,632 | $35K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,228 | $33K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,027 | $32K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,340 | $30K |
| 84484 | <1% | 5,765 | $29K | |
| 83735 | <1% | 5,820 | $28K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,293 | $25K |
| 81001 | <1% | 10,092 | $23K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,158 | $22K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,596 | $21K |
| 87040 | <1% | 2,765 | $21K | |
| 71110 | <1% | 1,483 | $21K | |
| 97001 | <1% | 802 | $20K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 490 | $20K |
| 86901 | <1% | 2,923 | $19K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,945 | $19K |
| 87430 | <1% | 1,846 | $19K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 502 | $18K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,529 | $16K |
| 80061 | Lipid panel | <1% | 1,972 | $16K |
| 82550 | <1% | 3,286 | $15K | |
| 96369 | <1% | 241 | $15K | |
| 83605 | <1% | 1,794 | $14K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 65 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,611 | $14K |
| 80074 | <1% | 279 | $13K | |
| 83690 | <1% | 2,367 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,362 | $13K |
| 87186 | <1% | 3,095 | $12K | |
| 85730 | <1% | 3,383 | $12K | |
| 84439 | <1% | 1,554 | $11K | |
| 81025 | <1% | 1,689 | $11K | |
| 83874 | <1% | 1,442 | $10K | |
| 86885 | <1% | 2,182 | $10K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 237 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,479 | $10K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,691 | $9K |
| 95811 | <1% | 74 | $9K | |
| 80320 | <1% | 768 | $9K | |
| 85610 | <1% | 3,988 | $9K | |
| 82947 | <1% | 3,705 | $8K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 489 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,956 | $7K |
| 86900 | <1% | 2,895 | $7K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 72 | $7K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 64 | $7K |
| 82150 | <1% | 1,262 | $7K | |
| 82607 | <1% | 535 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 319 | $6K |
| 84702 | <1% | 658 | $6K | |
| 86140 | <1% | 1,537 | $6K | |
| 85379 | <1% | 1,125 | $6K | |
| 86317 | <1% | 351 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 263 | $6K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 64 | $6K |
| 82565 | <1% | 615 | $5K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,461 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 682 | $5K |
| 82553 | <1% | 607 | $5K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 53 | $5K |
| 97162 | <1% | 56 | $5K | |
| 86701 | <1% | 487 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 31 | $4K |
| 86762 | <1% | 203 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 959 | $4K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 222 | $4K |
| 82728 | <1% | 283 | $3K | |
| 96376 | <1% | 3,165 | $3K | |
| G0378 | Hospital observation service, per hour | <1% | 2,210 | $3K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 15 | $3K |
| 97161 | <1% | 210 | $3K | |
| 59025 | Fetal non-stress test | <1% | 24 | $3K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 459 | $3K |
| 97597 | <1% | 154 | $3K | |
| 83540 | <1% | 621 | $3K | |
| 94760 | <1% | 670 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 321 | $3K |
| 36591 | <1% | 297 | $2K | |
| 82247 | <1% | 368 | $2K | |
| 80051 | <1% | 431 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 16 | $2K |
| 83655 | <1% | 137 | $2K | |
| 76641 | <1% | 61 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 46 | $2K |
| 73562 | <1% | 96 | $2K | |
| 86592 | <1% | 404 | $2K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 12 | $2K |
| 87070 | <1% | 210 | $2K | |
| 87210 | <1% | 393 | $2K | |
| 73630 | <1% | 83 | $2K | |
| 74022 | <1% | 82 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,807 | $2K |
| 73030 | <1% | 95 | $1K | |
| 0001A | <1% | 54 | $1K | |
| 83550 | <1% | 245 | $1K | |
| 84703 | <1% | 191 | $1K | |
| 87150 | <1% | 25 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,299 | $1K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,796 | $1K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 33 | $1K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 144 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,148 | $994.19 |
| 82803 | <1% | 44 | $792.88 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 743 | $725.70 |
| 73610 | <1% | 51 | $643.32 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 501 | $637.16 |
| 72100 | <1% | 29 | $598.63 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 650 | $531.60 |
| 36600 | <1% | 44 | $528.13 | |
| 94664 | <1% | 255 | $522.96 | |
| 86696 | <1% | 12 | $521.92 | |
| 74018 | <1% | 30 | $509.33 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,283 | $504.80 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,404 | $454.23 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $410.80 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,155 | $383.48 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,892 | $379.12 |
| 85652 | <1% | 156 | $342.57 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 919 | $308.73 |
| 76830 | Ultrasound, transvaginal | <1% | 15 | $285.66 |
| 82746 | <1% | 49 | $262.49 | |
| 86695 | <1% | 12 | $257.45 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 369 | $244.14 |
| 84145 | <1% | 13 | $229.52 | |
| 0002A | <1% | 17 | $210.80 | |
| 87081 | <1% | 25 | $208.34 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 334 | $204.09 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,153 | $196.20 |
| 85651 | <1% | 71 | $173.15 | |
| 80076 | <1% | 21 | $161.16 | |
| 90686 | <1% | 31 | $129.12 | |
| 84550 | <1% | 35 | $117.24 | |
| 97116 | <1% | 31 | $104.81 | |
| 82950 | <1% | 12 | $75.50 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 20 | $75.39 |
| 82248 | <1% | 17 | $63.66 | |
| J3490 | Unclassified drugs | <1% | 261 | $25.30 |
| 99406 | <1% | 400 | $25.12 | |
| 82043 | <1% | 15 | $16.54 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 226 | $8.13 |
| G0008 | Administration of influenza virus vaccine | 0% | 29 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 31 | $0.00 |
| 97762 | 0% | 30 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 43 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 176 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 20 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOLWELL, MELODIE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Drew Memorial Hospital, INC | Monticello, AR | $280K |
| Drew Memorial Hospital, INC | Monticello, AR | $180K |
| Drew Professional Services LLC | Monticello, AR | $6K |
| Drew Surgical Services LLC | Monticello, AR | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.